PCN Insights, News, Videos, and More
News
07/23/2024
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug...
07/23/2024
Psych Congress Network
News
07/22/2024
Including non-specific effects, approximately 15% or 1 in 6 to 7 patients experience antidepressant discontinuation symptoms, according to recent systematic review and meta-analysis results published in The Lancet Psychiatry.Â
Including non-specific effects, approximately 15% or 1 in 6 to 7 patients experience antidepressant discontinuation symptoms, according to recent systematic review and meta-analysis results published in The Lancet Psychiatry.Â
Including non-specific effects,...
07/22/2024
Psych Congress Network
Podcasts
07/22/2024
Drs Podesta and Carbray examine available treatments, recommended strategies, and how clinicians can better communicate with patients with this comorbidity.
Drs Podesta and Carbray examine available treatments, recommended strategies, and how clinicians can better communicate with patients with this comorbidity.
Drs Podesta and Carbray examine...
07/22/2024
Psych Congress Network
News
07/17/2024
Pneumonia in patients with schizophrenia is associated with the use of specific antipsychotics, according to study findings published in JAMA Psychiatry.
Pneumonia in patients with schizophrenia is associated with the use of specific antipsychotics, according to study findings published in JAMA Psychiatry.
Pneumonia in patients with...
07/17/2024
Psych Congress Network
News
07/16/2024
Combining certain medications or psychotherapy with TMS or tDCS may decrease symptoms of MDD, though some limitations still exist, according to a review published in the Harvard Review of Psychiatry.Â
Combining certain medications or psychotherapy with TMS or tDCS may decrease symptoms of MDD, though some limitations still exist, according to a review published in the Harvard Review of Psychiatry.Â
Combining certain medications or...
07/16/2024
Psych Congress Network
Q&As
07/16/2024
Nishi Bhopal, MD, discusses how mental health clinicians can more closely incorporate sleep disorder screening, diagnosis, and treatment into their practices.
Nishi Bhopal, MD, discusses how mental health clinicians can more closely incorporate sleep disorder screening, diagnosis, and treatment into their practices.
Nishi Bhopal, MD, discusses how...
07/16/2024
Psych Congress Network
News
07/16/2024
PTSD, MDD, and PGD appear highly prevalent and comorbid among bereaved US adults, particularly those who experienced a traumatic loss of a psychologically close other.
PTSD, MDD, and PGD appear highly prevalent and comorbid among bereaved US adults, particularly those who experienced a traumatic loss of a psychologically close other.
PTSD, MDD, and PGD appear highly...
07/16/2024
Psych Congress Network
Videos
07/15/2024
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN,...
07/15/2024
Psych Congress Network
Videos
07/15/2024
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN,...
07/15/2024
Psych Congress Network
Videos
07/15/2024
Charles Raison, MD, discusses first-line treatment options for insomnia.
Charles Raison, MD, discusses first-line treatment options for insomnia.
Charles Raison, MD, discusses...
07/15/2024
Neurology
